CYTEK BIOSCIENCES, INC. Operating Expenses
CYTEK BIOSCIENCES, INC. (CTKB) reported Operating Expenses of $39.74 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-05
- CYTEK BIOSCIENCES, INC. operating expenses for the quarter ending 2026-06-30 was $39.74M, a 15.22% increase year-over-year.
- CYTEK BIOSCIENCES, INC. operating expenses for the quarter ending 2026-03-31 was $39.72M, a 13.05% increase year-over-year.
- CYTEK BIOSCIENCES, INC. operating expenses for the quarter ending 2025-12-31 was $38.48M, a 25.48% increase year-over-year.
- CYTEK BIOSCIENCES, INC. operating expenses for the quarter ending 2025-09-30 was $36.74M, a 10.50% increase year-over-year.
- CYTEK BIOSCIENCES, INC. operating expenses for fiscal 2025 was $144.84M, a 10.04% increase from fiscal 2024.
- CYTEK BIOSCIENCES, INC. operating expenses for fiscal 2024 was $131.63M, a 4.11% decline from fiscal 2023.
- CYTEK BIOSCIENCES, INC. operating expenses for fiscal 2023 was $137.27M, a 33.56% increase from fiscal 2022.
- CYTEK BIOSCIENCES, INC. operating expenses for fiscal 2022 was $102.78M, a 46.85% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $39.74M 10-Q · filed 2026-08-05 | $79.46M 10-Q · filed 2026-08-05 | $117.94M derived: sum of 3 quarters · filed 2026-08-05 | $154.68M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $39.72M 10-Q · filed 2026-05-07 | $78.20M derived: sum of 2 quarters · filed 2026-05-07 | $114.94M derived: sum of 3 quarters · filed 2026-05-07 | $149.43M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $38.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $75.22M derived: sum of 2 quarters · filed 2026-02-26 | $109.71M derived: sum of 3 quarters · filed 2026-08-05 | $144.84M 10-K · filed 2026-02-26 |
| 2025-09-30 | $36.74M 10-Q · filed 2025-11-05 | $71.23M derived: sum of 2 quarters · filed 2026-08-05 | $106.36M 10-Q · filed 2025-11-05 | $137.03M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $34.49M 10-Q · filed 2026-08-05 | $69.62M 10-Q · filed 2026-08-05 | $100.29M derived: sum of 3 quarters · filed 2026-08-05 | $133.54M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $35.13M 10-Q · filed 2026-05-07 | $65.80M derived: sum of 2 quarters · filed 2026-05-07 | $99.05M derived: sum of 3 quarters · filed 2026-05-07 | $133.01M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $30.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $63.92M derived: sum of 2 quarters · filed 2026-02-26 | $97.88M derived: sum of 3 quarters · filed 2026-02-26 | $131.63M 10-K · filed 2026-02-26 |
| 2024-09-30 | $33.25M 10-Q · filed 2025-11-05 | $67.22M derived: sum of 2 quarters · filed 2025-11-05 | $100.96M 10-Q · filed 2025-11-05 | $134.15M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $33.96M 10-Q · filed 2025-08-06 | $67.71M 10-Q · filed 2025-08-06 | $100.89M derived: sum of 3 quarters · filed 2026-02-26 | $134.49M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $33.75M 10-Q · filed 2025-05-08 | $66.93M derived: sum of 2 quarters · filed 2026-02-26 | $100.53M derived: sum of 3 quarters · filed 2026-02-26 | $137.82M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $33.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $66.78M derived: sum of 2 quarters · filed 2026-02-26 | $104.07M derived: sum of 3 quarters · filed 2026-02-26 | $137.27M 10-K · filed 2026-02-26 |
| 2023-09-30 | $33.60M 10-Q · filed 2024-11-07 | $70.89M derived: sum of 2 quarters · filed 2024-11-07 | $104.09M 10-Q · filed 2024-11-07 | $133.38M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $37.29M 10-Q · filed 2024-08-06 | $70.49M 10-Q · filed 2024-08-06 | $99.78M derived: sum of 3 quarters · filed 2025-02-28 | $125.28M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $33.20M 10-Q · filed 2024-05-08 | $62.49M derived: sum of 2 quarters · filed 2025-02-28 | $87.99M derived: sum of 3 quarters · filed 2025-02-28 | $113.44M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $29.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $54.79M derived: sum of 2 quarters · filed 2025-02-28 | $80.24M derived: sum of 3 quarters · filed 2025-02-28 | $102.78M 10-K · filed 2025-02-28 |
| 2022-09-30 | $25.50M 10-Q · filed 2023-11-14 | $50.95M derived: sum of 2 quarters · filed 2023-11-14 | $73.49M 10-Q · filed 2023-11-14 | $95.81M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-06-30 | $25.45M 10-Q · filed 2023-08-08 | $47.99M 10-Q · filed 2023-08-08 | $70.31M derived: sum of 3 quarters · filed 2024-03-13 | $88.69M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-03-31 | $22.53M 10-Q · filed 2023-05-09 | $44.85M derived: sum of 2 quarters · filed 2024-03-13 | $63.23M derived: sum of 3 quarters · filed 2024-03-13 | $79.17M derived: sum of 4 quarters · filed 2024-03-13 |
| 2021-12-31 | $22.32M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $40.70M derived: sum of 2 quarters · filed 2024-03-13 | $56.63M derived: sum of 3 quarters · filed 2024-03-13 | $69.99M 10-K · filed 2024-03-13 |
| 2021-09-30 | $18.38M 10-Q · filed 2022-11-09 | $34.31M derived: sum of 2 quarters · filed 2022-11-09 | $47.67M 10-Q · filed 2022-11-09 | $59.24M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $15.93M 10-Q · filed 2022-08-10 | $29.29M 10-Q · filed 2022-08-10 | $40.86M derived: sum of 3 quarters · filed 2023-03-01 | $49.77M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $13.35M 10-Q · filed 2022-05-12 | $24.93M derived: sum of 2 quarters · filed 2023-03-01 | $33.83M derived: sum of 3 quarters · filed 2023-03-01 | $42.32M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $11.57M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $20.48M derived: sum of 2 quarters · filed 2023-03-01 | $28.97M derived: sum of 3 quarters · filed 2023-03-01 | $38.05M 10-K · filed 2023-03-01 |
| 2020-09-30 | $8.90M 10-Q · filed 2021-11-12 | $17.39M derived: sum of 2 quarters · filed 2021-11-12 | $26.48M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $8.49M 10-Q · filed 2021-09-03 | $17.57M 10-Q · filed 2021-09-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |